Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing

摘要: Traditionally, xenograft models have been used to study tumors in vivo. However, their utility is reduced by the use of tumor cell lines for implantation. Tumorgrafts (TGs; also known as patient-derived xenografts (PDXs)), which involve samples, are increasingly recognized more representative than traditional xenografts. Furthermore, we showed previously that renal carcinoma (RCC) TGs retain histology, gene expression, DNA copy number alterations, mutations and treatment responsiveness patient tumors. In skilled hands, implantations require ≤5 min per mouse, typically grow 1 cm 1-4 months. Here outline process implantation RCC samples into kidneys immunodeficient mice, well s.c. preclinical drug testing, including guidelines design execution trials. extensive applications besides therapeutic studies may identify biomarkers mechanisms resistance. addition, they provide insights biology.